GENELUX CORP (GNLX)
US36870H1032 - Common Stock
GNLX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 586 industry peers in the Biotechnology industry. While GNLX seems to be doing ok healthwise, there are quite some concerns on its profitability. GNLX has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
GNLX had negative earnings in the past year.
GNLX had a negative operating cash flow in the past year.
In the past 5 years GNLX always reported negative net income.
GNLX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GNLX has a Return On Assets of -101.43%. This is in the lower half of the industry: GNLX underperforms 79.15% of its industry peers.
With a Return On Equity value of -145.29%, GNLX is not doing good in the industry: 64.96% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.43% | ||
| ROE | -145.29% | ||
| ROIC | N/A |
ROA(3y)-132.38%
ROA(5y)-169.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GNLX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GNLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GNLX has more shares outstanding
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
GNLX has an Altman-Z score of -6.22. This is a bad value and indicates that GNLX is not financially healthy and even has some risk of bankruptcy.
GNLX has a Altman-Z score of -6.22. This is in the lower half of the industry: GNLX underperforms 67.01% of its industry peers.
There is no outstanding debt for GNLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.22 |
ROIC/WACCN/A
WACC8.04%
2.3 Liquidity
A Current Ratio of 3.69 indicates that GNLX has no problem at all paying its short term obligations.
GNLX has a Current ratio of 3.69. This is comparable to the rest of the industry: GNLX outperforms 40.85% of its industry peers.
A Quick Ratio of 3.69 indicates that GNLX has no problem at all paying its short term obligations.
GNLX has a Quick ratio (3.69) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.69 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
GNLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -508.25%.
Looking at the last year, GNLX shows a very negative growth in Revenue. The Revenue has decreased by -98.46% in the last year.
EPS 1Y (TTM)-508.25%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-94.28%
Revenue 1Y (TTM)-98.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-100%
3.2 Future
The Earnings Per Share is expected to grow by 21.90% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 291.00% on average over the next years. This is a very strong growth
EPS Next Y21.18%
EPS Next 2Y1.52%
EPS Next 3Y5.99%
EPS Next 5Y21.9%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y436.1%
Revenue Next 5Y291%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GNLX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNLX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.52%
EPS Next 3Y5.99%
5. Dividend
5.1 Amount
No dividends for GNLX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENELUX CORP
NASDAQ:GNLX (5/17/2024, 7:02:14 PM)
After market: 3.99 +0.34 (+9.32%)3.65
+0.05 (+1.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap98.08M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -101.43% | ||
| ROE | -145.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.69 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-508.25%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y21.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-98.46%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y